Incyte Corp

INCY

Company Profile

  • Business description

    Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

  • Contact

    1801 Augustine Cut-Off
    WilmingtonDE19803
    USA

    T: +1 302 498-6700

    E: [email protected]

    https://www.incyte.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    2,617

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,053.20142.30-1.74%
CAC 407,790.71125.37-1.58%
DAX 4022,163.49298.03-1.33%
Dow JONES (US)42,000.28416.381.00%
FTSE 1008,582.8176.04-0.88%
HKSE23,119.58307.02-1.31%
NASDAQ17,263.9659.03-0.34%
Nikkei 22535,617.561,502.77-4.05%
NZX 50 Index12,270.0017.46-0.14%
S&P 5005,605.8024.860.45%
S&P/ASX 2007,843.40138.60-1.74%
SSE Composite Index3,335.7515.56-0.46%

Market Movers